ABCG2 Protein Levels and Association to Response to First-Line Irinotecan-Based Therapy for Patients with Metastatic Colorectal Cancer
Authors:
- Jesper Andreas PalshofJPJesper Andreas Palshof
- Camilla Natasha CederbyeCCCamilla Natasha Cederbye
- Estrid Vilma Solyom HøgdallEstrid Vilma Solyom Høgdall
- Tim Svenstrup PoulsenTPTim Svenstrup Poulsen
- Dorte LinnemannDLDorte Linnemann
- Sune Boris NygaardSNSune Boris Nygaard
- Jan StenvangJan Stenvang
- Ib Jarle ChristensenICIb Jarle Christensen
- Benny Vittrup JensenBJBenny Vittrup Jensen
- Per PfeifferPPPer Pfeiffer
- Nils BrünnerNBNils Brünner
- Mette YilmazMYMette Yilmaz
Open Access
- 16 July 2020
- journal article
- research article
- Published by MDPI AG in International Journal of Molecular Sciences
- Vol. 21 (14) , 5027
Abstract
In this study we investigated the use of cancer cell protein expression of ABCG2 to predict efficacy of systemic first-line irinotecan containing therapy in patients with metastatic colorectal cancer (mCRC). From a Danish national cohort, we identified 119 mCRC patients treated with irinotecan containing therapy in first-line setting. Among these, 108 were eligible for analyses. Immunohistochemistry (IHC) analyses were performed on the primary tumor tissue in order to classify samples as high or low presence of ABCG2 protein. Data were then associated with patient outcome (objective response (OR), progression free survival (PFS) and overall survival (OS)). ABCG2 protein expression in the basolateral membrane was high (score 3+) in 33% of the patients. Exploratory analyses revealed a significant interaction between ABCG2 score, adjuvant treatment and OR (p = 0.041) in the 101 patients with evaluable disease. Patients with low ABCG2 (score 0–2) and no prior adjuvant therapy had a significantly higher odds ratio of 5.6 (Confidence Interval (CI) 1.68–18.7; p = 0.005) for obtaining OR. In contrast, no significant associations between ABCG2 expression and PFS or OS were found. These results suggest that measurement of the ABCG2 drug efflux pump might be used to select patients with mCRC for irinotecan treatment. However, additional studies are warranted before conclusions regarding a clinical use can be made. Moreover, patients with high ABCG2 immunoreactivity could be candidates for specific ABCG2 inhibition treatment in combination with irinotecan.Keywords
Funding Information
- IMK Almene (102-0489/13-3000)
- Savværksejer Ivita and Jeppe Juhl Foundation, (102-5212/18-3000)
- Danish Cancer Society Research Center (DK001, DCSR010)
- Kathrine and Vigo Skovgaard Foundation (KVSF010)
- The Danish Strategic Research Counsel (DSRC010)
- I.M. Daehnfeldt Foundation (IMDF010)
This publication has 36 references indexed in Scilit:
- Reporting recommendations for tumor marker prognostic studies (REMARK): explanation and elaborationBMC Medicine, 2012
- HER2 testing in gastric cancer: a practical approachLaboratory Investigation, 2012
- Effect of 5-FU and MTX on the Expression of Drug-resistance Related Cancer Stem Cell Markers in Non-small Cell Lung Cancer CellsThe Korean Journal of Physiology & Pharmacology, 2012
- The ABCG family of membrane‐associated transporters: you don't have to be big to be mightyBritish Journal of Pharmacology, 2011
- Use of Archived Specimens in Evaluation of Prognostic and Predictive BiomarkersJNCI: Journal of the National Cancer Institute, 2009
- ABCG2: A perspectiveAdvanced Drug Delivery Reviews, 2009
- ABCG2 overexpression in colon cancer cells resistant to SN38 and in irinotecan‐treated metastasesInternational Journal of Cancer, 2004
- FOLFIRI Followed by FOLFOX6 or the Reverse Sequence in Advanced Colorectal Cancer: A Randomized GERCOR StudyJournal of Clinical Oncology, 2004
- Multidrug resistance in cancer: role of ATP–dependent transportersNature Reviews Cancer, 2002
- New Guidelines to Evaluate the Response to Treatment in Solid TumorsJNCI: Journal of the National Cancer Institute, 2000